Immunoprotection against toxic biomarkers is retained during Parkinson's disease progression
Immunoprotection against toxic biomarkers is retained during Parkinson's disease progression
复制标题
DOI：
10.1016/j.jneuroim.2010.12.001
复制
发表时间：
2011-04-01
影响因子：
3.3
通讯作者：
Morozova-Roche, Ludmilla A.
中科院分区：
文献类型：
--
作者：
Gruden, Marina A.;Sewell, Robert D. E.;Morozova-Roche, Ludmilla A.
目的是确定体液免疫反应对主要生物标志物（α -突触核蛋白单体、其毒性低聚物或原纤维、多巴胺和S100B）和帕金森病发展过程中细胞免疫之间的任何可能联系。在病程为5年的帕金森病患者中，分别有72%、56%和17%的患者对α -突触核蛋白单体、低聚物和原纤维的自身抗体滴度升高。此外，在5年患者组中，多巴胺和S100B滴度升高（96%和89%）。在10年的患者中，所有这些数值都下降了。此外，在帕金森患者队列中，CD3+、CD4+、CD8+ t淋巴细胞和b淋巴细胞亚群下降，表明这些淋巴细胞亚群的减少与疾病相关。(C) 2010 Elsevier B.V.版权所有
The aim was to ascertain any possible linkage between humoral immune responses to principal biomarkers (alpha-synuclein monomers, its toxic oligomers or fibrils, dopamine and S100B) and cellular immunity in Parkinson's disease development. There were elevated autoantibody titers to alpha-synuclein monomers, oligomers plus fibrils in 72%, 56%, and 17% of Parkinsonian patients respectively with a 5-year disease duration. Additionally, there were increased titers to dopamine and S100B (96% and 89%) in the 5-year patient group. All of these values subsided in 10-year sufferers.Furthermore, CD3+, CD4+, CD8+ T-lymphocyte and B-lymphocyte subsets declined in the patient cohort during Parkinsonism indicating disease associated reductions in these lymphocyte subsets. (C) 2010 Elsevier B.V. All rights reserved.